Phase B therapy by risk class (MRD and clinical)
| Risk class . | Phase B therapy, no. . | ||||
|---|---|---|---|---|---|
| MRD . | Clinical . | Maintenance . | SCT . | H/C . | None (reason) . |
| MRDneg (n = 58) | SR (n = 35) | 32 | 1 | 2 | — |
| HR (n = 18) | 15 | 2 | 1 | — | |
| VHR (n = 5) | 0 | 0 | 4 | 1 (relapse) | |
| MRDpos (n = 54) | SR (n = 26) | 3 | 10 | 7 | 6 (relapse 5, refusal 1) |
| HR (n = 19) | 1 | 8 | 4 | 6 (relapse 5, refusal 1) | |
| VHR (n = 9) | 0 | 4 | 3 | 2 (relapse 1, toxicity 1) | |
| MRDu/k (n = 30) | SR (n = 10) | 8 | 0 | 1 | 1 (refusal) |
| HR (n = 15) | 4 | 1 | 8 | 2 (relapse 1, off study 1) | |
| VHR (n = 3) | 0 | 0 | 2 | 1 (relapse) | |
| Undefined (T-cell) (n = 2) | 1 | 0 | 0 | 1 (relapse) | |
| Risk class . | Phase B therapy, no. . | ||||
|---|---|---|---|---|---|
| MRD . | Clinical . | Maintenance . | SCT . | H/C . | None (reason) . |
| MRDneg (n = 58) | SR (n = 35) | 32 | 1 | 2 | — |
| HR (n = 18) | 15 | 2 | 1 | — | |
| VHR (n = 5) | 0 | 0 | 4 | 1 (relapse) | |
| MRDpos (n = 54) | SR (n = 26) | 3 | 10 | 7 | 6 (relapse 5, refusal 1) |
| HR (n = 19) | 1 | 8 | 4 | 6 (relapse 5, refusal 1) | |
| VHR (n = 9) | 0 | 4 | 3 | 2 (relapse 1, toxicity 1) | |
| MRDu/k (n = 30) | SR (n = 10) | 8 | 0 | 1 | 1 (refusal) |
| HR (n = 15) | 4 | 1 | 8 | 2 (relapse 1, off study 1) | |
| VHR (n = 3) | 0 | 0 | 2 | 1 (relapse) | |
| Undefined (T-cell) (n = 2) | 1 | 0 | 0 | 1 (relapse) | |